Unknown PHASE4 INTERVENTIONAL 4-arm NCT00902083

rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors (rAd-p53)

Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors

Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd

Conditions Advanced Oral and Maxillofacial Malignant Tumors

Interventions p53 gene therapy p53 gene with surgery p53 with chemotherapy surgery

Updated 5 times since 2017 Last updated: Apr 6, 2012 Started: Jun 30, 2009 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Advanced Oral and Maxillofacial Malignant Tumors, this trial is ongoing. The trial is conducted by Shenzhen SiBiono GeneTech Co.,Ltd and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen SiBiono GeneTech Co.,Ltd

Data source: Shenzhen SiBiono GeneTech Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China